Categories AlphaGraphs, Earnings, Health Care

Infographic: Moderna (MRNA) Q2 2023 Earnings Results

Moderna, Inc. (NASDAQ: MRNA) reported second quarter 2023 earnings results today.

Total revenue dropped to $344 million from $4.7 billion in the same period last year, mainly due to a decrease in sales of the company’s COVID-19 vaccine.

Net loss was $1.4 billion, or $3.62 per share, compared to net income of $2.2 billion, or $5.24 per share, last year.  

Product sales were $293 million, down 94% compared to last year, mainly due to lower sales volume. The company reported $0.3 billion in COVID-19 vaccine sales in Q2.

For FY2023, the company is expecting COVID-19 sales of $6-8 billion, dependent on US vaccination rates.

Most Popular

Nike (NKE) looks set to beat hurdles and build a brighter future

Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business

Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company

Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as

Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications

Add Comment
Viewing Highlight